Online inquiry

IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5918MR)

This product GTTS-WQ5918MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5918MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2413MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 145
GTTS-WQ4656MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ14958MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ1895MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGEN2034
GTTS-WQ13271MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-06252616
GTTS-WQ1901MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ11503MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ4617MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-986015
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW